Karyopharm Therapeut
(KPTI)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 62,506 | 52,891 | 136,252 | 196,808 | 88,399 |
| Marketable Securities | 46,236 | 139,212 | 142,779 | 38,156 | 163,322 |
| Receivables | 30,766 | 26,962 | 47,086 | 22,497 | 12,881 |
| Inventories | 4,739 | 3,043 | 4,224 | 4,106 | 2,644 |
| TOTAL | $156,492 | $233,921 | $350,162 | $275,606 | $276,531 |
| Non-Current Assets | |||||
| PPE Net | 400 | 606 | 1,139 | 1,642 | 2,219 |
| Investments And Advances | 0 | 0 | 0 | 0 | 24,215 |
| Other Non-Current Assets | 7,526 | 5,911 | 6,871 | 28,057 | 10,085 |
| TOTAL | $7,926 | $6,517 | $8,010 | $29,699 | $36,519 |
| Total Assets | $164,418 | $240,438 | $358,172 | $305,305 | $313,050 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 24,426 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 5,107 | 3,123 | 2,773 | 1,603 | 4,450 |
| Accrued Expenses | 60,652 | 61,394 | 58,415 | 69,121 | 52,930 |
| Other current liabilities | 1,641 | 1,654 | 1,848 | 678 | 609 |
| TOTAL | $92,264 | $69,479 | $65,908 | $73,718 | $60,203 |
| Non-Current Liabilities | |||||
| Long Term Debt | 94,603 | N/A | N/A | N/A | N/A |
| Deferred Revenues | N/A | N/A | N/A | N/A | 297 |
| Other Non-Current Liabilities | 163,568 | 307,165 | 308,920 | 311,260 | 202,301 |
| TOTAL | $258,171 | $307,165 | $308,920 | $311,260 | $202,301 |
| Total Liabilities | $350,435 | $376,644 | $374,828 | $384,978 | $262,504 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 8,420 | 7,675 | 7,560 | 5,280 | 4,978 |
| Common Shares | 13 | 12 | 12 | 8 | 7 |
| Retained earnings | -1,563,460 | -1,487,038 | -1,343,939 | -1,178,648 | -1,069,611 |
| Other shareholders' equity | -356 | -161 | -638 | 191 | 518 |
| TOTAL | $-186,017 | $-136,206 | $-16,656 | $-79,673 | $50,546 |
| Total Liabilities And Equity | $164,418 | $240,438 | $358,172 | $305,305 | $313,050 |